Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Artificial Intelligence Cancer Diagnostics

Reading Paige’s Playbook For Cancer Diagnostics

  • Interviews

Executive Summary

Paige CEO Andy Moye talked to Medtech Insight about the company’s current offerings in the prostate and breast cancer markets, as well as its future ambitions and general strategy.

You may also be interested in...



Minute Insight: Paige Strikes It Big With Microsoft Partnership

The two tech companies – one software giant, the other focused on oncology – will work together on what will likely be the largest artificial intelligence model of its kind.

Minute Insight: Aignostics Completes Raise To Fund AI Pathology Platform

The company has raised €14m to develop its AI-based pathology software which will make diagnosing cancer faster and easier.

Paige Secures Eighth CE Mark For Cancer Identification AI

The Memorial Sloan Kettering spin-out has received CE-IVD and UKCA marks for its artificial intelligence software designed to identify HER2 expression in biopsies.

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Artificial Intelligence Cancer Diagnostics
Latest Headlines

Oxford Biodynamics Releases EpiSwitch Prostate Cancer Test Early

Minute Insight: Enovis Buys Lima To Great Billion-Dollar Recon Business

Contingency Planning: Guidance Doc Details Handling Clinical Trials During Emergencies

ZimVie Wins Investigational Device Exemption For Disc Replacement Device, Plans To Begin Study

See All
UsernamePublicRestriction

Register

MT145603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By